Splash

Investors

We are committed to delivering our strategy and creating value for our shareholders.
Splash
Investors
Latest Results

Latest Results

We’re pleased to announce our latest results.

Download Results

Latest News

Latest Events

November 23 2020Regulatory
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank

Non-dilutive capital to provide further financial flexibility LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it has entered

November 9 2020Regulatory
Verona Pharma Announces November 2020 Virtual Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the

October 29 2020Regulatory
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot clinical study in U.S. patients hospitalized with COVID-19 Conference call today at 9:00 a.m. EDT / 1:00 p.m. GMT LONDON and RALEIGH, N.C., Oct.

View all regulatory news
Splash

© Verona Pharma plc 2020. All rights reserved